The investigators demonstrated that palbociclib sensitive ER+/HER2− breast cancer cells are characterized by increased aerobic glycolysis whereas ER+/HER2+ cells increased glycolytic catabolism as they develop resistance. Here, ESR1 is linked to breast carcinoma.